Latest news and press releases about Adagene Inc. (ADAG): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials.
Price
| Price | $3.17 |
| Market Cap | $119M |
| Exchange | NASDAQ |
| Country | CN |
Valuation Ratios
| Price / Book | 1.31 |
| EV / EBITDA | -0.59 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -29.09% |
| Return on Invested Capital | -19.62% |
| Return on Assets | -15.39% |
| Gross Margin | 94.22% |
| Operating Margin | -240.31% |
| Net Margin | -220.66% |
Related companies: ACET · CRVO · FBIO · GANX · LITS · NRXP · NTRB
Explore sector: Healthcare · Biotechnology
More sections of ADAG: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks